

CITATION REPORT

List of articles citing

Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States

DOI: 10.1007/s40273-018-0745-z

Pharmacoeconomics, 2019, 37, 391-405.

Source: <https://exaly.com/paper-pdf/74580264/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
31	Niraparib cost effective for recurrent ovarian cancer?. <i>PharmacoEconomics & Outcomes News</i> , 2018 , 818, 20-20	0.1	
30	Comment on: "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States". <i>Pharmacoeconomics</i> , 2019 , 37, 1065-1067	4.4	4
29	Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States". <i>Pharmacoeconomics</i> , 2019 , 37, 963-964	4.4	3
28	Response to Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"U <i>Pharmacoeconomics</i> , 2019 , 37, 965-967	4.4	0
27	Real-world evidence of poly ADP-ribose polymerase inhibitors in the treatment of ovarian cancer: A systematic literature review. <i>Journal of Oncology Pharmacy Practice</i> , 2020 , 26, 1977-1986	1.7	2
26	Role of hyperthermic intraperitoneal chemotherapy in ovarian cancer. <i>Chinese Clinical Oncology</i> , 2020 , 9, 44	2.3	0
25	Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 1569-1575	3.5	5
24	Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 1576-1582	3.5	4
23	A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer. <i>Pharmacoeconomics</i> , 2020 , 38, 1201-1218	4.4	0
22	Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service. <i>Clinical Therapeutics</i> , 2020 , 42, 1192-1209.e12	3.5	2
21	Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 903-915	3.5	15
20	The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer. <i>Pharmacoeconomics</i> , 2021 , 39, 231-241	4.4	2
19	Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by mutation status for platinum-sensitive relapsed ovarian cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 21, 441-448	2.2	1
18	Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients. <i>Gynecologic Oncology</i> , 2021 , 160, 793-799	4.9	2
17	Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic. <i>Frontiers in Pharmacology</i> , 2021 , 12, 632818	5.6	1
16	Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021 , 27, 1377-1387	1.9	
15	Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1528-1536	7.3	6

14	Targeting Six Hallmarks of Cancer in Ovarian Cancer Therapy. <i>Current Cancer Drug Targets</i> , 2020 , 20, 853-867	2.8	o
13	Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?. <i>Gynecologic Oncology</i> , 2021 ,	4.9	o
12	Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma. <i>Frontiers in Pharmacology</i> , 2021 , 12, 732912	5.6	2
11	A DNA damage nanoamplifier for the chemotherapy of triple-negative breast cancer via DNA damage induction and repair blocking. <i>International Journal of Pharmaceutics</i> , 2022 , 622, 121897	6.5	
10	Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials. <i>Journal of Market Access & Health Policy</i> , 2022 , 10,	3.7	o
9	Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review. <i>Frontiers in Pharmacology</i> , 13,	5.6	
8	Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis. 12,		o
7	Cost-effectiveness of PARP inhibitors in malignancies: A systematic review. 2022 , 17, e0279286		1
6	Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany. 2022 , 17, e0278460		o
5	Cost-Effectiveness of Risk-Reducing Surgery for Breast and Ovarian Cancer Prevention: A Systematic Review. 2022 , 14, 6117		o
4	Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China. 13,		o
3	Projecting overall survival in health-economic models: uncertainty and maturity of data. 1-12		o
2	Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment.		o
1	The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer. 2023 , 23, 317-325		o